Small Molecules, Big Decisions: Where Do TYK2 Inhibitors Fit in Psoriasis Treatment?

Please visit answersincme.com/860/IME-018263-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by April W. Armstrong, MD, MPH and Lawrence J. Green, MD. In this activity, experts in psoriasis review the latest evidence on approved and emerging TYK2 inhibitors for patients with moderate to severe plaque psoriasis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in the treatment of patients with moderate to severe plaque psoriasis; Differentiate TYK2 signaling from JAK pathways and their relevance to clinical practice; and Review clinical trial data on approved and emerging TYK2 inhibitors for patients with moderate to severe plaque psoriasis.